Recovery from CMV esophagitis after allogeneic bone marrow transplantation using non-myeloablative conditioning: the role of immunosuppression.
Cytomegalovirus (CMV) positive recipients of CMV negative bone marrow bear a significantly higher risk of developing CMV disease compared to all other constellations. Here, we report a case of severe CMV induced esophagitis after allogeneic bone marrow transplantation for paroxysmal nocturnal hemoglobinuria. The patient developed the first symptoms between day 10 and 20 after dose reduced conditioning and HLA-matched unrelated stem cell transplantation. Esophageal tissue biopsies as well as peripheral blood proved positive for CMV DNA by PCR. Treatment with acyclovir, ganciclovir, foscarnet, cidofovir, and immunoglobulines resulted in elimination of CMV in peripheral blood but not in clinical improvement. Only tapering of cyclosporine at day +120 eventually led to the development of CMV-specific T-cells and resolution of esophagitis.
Fiegl
Michael
M
Clinical Cooperative Group Hematopoietic Cell Transplantation, Department of Internal Medicine III, Ludwig Maximilians University (LMU), Marchioninistr. 15, 81377 Munich, Germany.
Gerbitz
Armin
A
Gaeta
Antonia
A
Campe
Hartmut
H
Jaeger
Gundula
G
Kolb
Hans-Jochem
HJ
D000998:Antiviral Agents / Q000627:therapeutic use; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D003586:Cytomegalovirus Infections / Q000188:drug therapy* / Q000209:etiology*; D004359:Drug Therapy, Combination; D004941:Esophagitis / Q000188:drug therapy / Q000209:etiology*; D005260:Female; D006457:Hemoglobinuria, Paroxysmal / Q000150:complications / Q000628:therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D008875:Middle Aged; D013601:T-Lymphocytes / Q000276:immunology; D019172:Transplantation Conditioning / Q000379:methods*; D014184:Transplantation, Homologous
D000998:Antiviral Agents; D007166:Immunosuppressive Agents